Fortress Biotech, Inc. (FBIO) stock
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.89+0.07 (+3.85%)
Close on Nov 18, 2026Market cap $69.51MP/E –Yield –
Fortress Biotech free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Fortress Biotech's free cash flow for the twelve months ending Dec 31, 2024 was -$80.19M. For fiscal 2024 it was -$80.19M. The highest annual figure on record is -$10.95M in fiscal 2011.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$80.19M | – |
| FY2023 | Dec 31, 2023 | -$128.29M | – |
| FY2022 | Dec 31, 2022 | -$182.12M | – |
| FY2021 | Dec 31, 2021 | -$121.11M | – |
| FY2020 | Dec 31, 2020 | -$85.61M | – |
| FY2019 | Dec 31, 2019 | -$97.31M | – |
| FY2018 | Dec 31, 2018 | -$105.93M | – |
| FY2017 | Dec 31, 2017 | -$81.95M | – |
| FY2016 | Dec 31, 2016 | -$52.18M | – |
| FY2015 | Dec 31, 2015 | -$20.66M | – |
| FY2014 | Dec 31, 2014 | -$16.33M | – |
| FY2013 | Dec 31, 2013 | -$29.69M | – |
| FY2012 | Dec 31, 2012 | -$23.25M | – |
| FY2011 | Dec 31, 2011 | -$10.95M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$12.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$34.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.22M | – |
| Q4 FY2022 | Dec 31, 2022 | -$47.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$44.25M | – |
| Q2 FY2022 | Jun 30, 2022 | -$41.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$48.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$40.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$36.15M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.18M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.37M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.42M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.94M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.76M | – |
| Q2 FY2019 | Jun 30, 2019 | -$28.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.63M | – |
| Q4 FY2018 | Dec 31, 2018 | -$22.50M | – |
| Q3 FY2018 | Sep 30, 2018 | -$26.89M | – |
| Q2 FY2018 | Jun 30, 2018 | -$27.93M | – |
| Q1 FY2018 | Mar 31, 2018 | -$28.61M | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.51M | – |
| Q3 FY2017 | Sep 30, 2017 | -$25.63M | – |
| Q2 FY2017 | Jun 30, 2017 | -$24.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.74M | – |
| Q4 FY2016 | Dec 31, 2016 | -$18.58M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.28M | – |
See a number that looks wrong?